Physician profile
John Varga
NPI 1528288495
$63,563.07
in general payments reported to CMS, 2019-2025
11 companies · $12K in 2025
The $12K reported for 2025 was more than what 91% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $9,099 · 2021: $9,714 · 2022: $1,892 · 2024: $3,713 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Travel and Lodging: $1,906 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,136 · Food and Beverage: $413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,550.00 |
| Travel and Lodging | $1,905.95 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,135.81 |
| Food and Beverage | $412.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $28,486.33 | 2019-2022 | |
| Boehringer Ingelheim International Gmbh | $14,492.73 | 2019-2025 | Ofev |
| Amgen INC. | $8,213.68 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $6,983.24 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $4,493.00 | 2025 | |
| Horizon Therapeutics Plc | $600.00 | 2019 | |
| Celgene Corporation | $294.09 | 2024-2025 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Varga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.